JP2020503841A5 - - Google Patents

Download PDF

Info

Publication number
JP2020503841A5
JP2020503841A5 JP2019519313A JP2019519313A JP2020503841A5 JP 2020503841 A5 JP2020503841 A5 JP 2020503841A5 JP 2019519313 A JP2019519313 A JP 2019519313A JP 2019519313 A JP2019519313 A JP 2019519313A JP 2020503841 A5 JP2020503841 A5 JP 2020503841A5
Authority
JP
Japan
Prior art keywords
cell
disorder
disease
cells
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019519313A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503841A (ja
JP7213799B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2017/051133 external-priority patent/WO2018069927A1/en
Publication of JP2020503841A publication Critical patent/JP2020503841A/ja
Publication of JP2020503841A5 publication Critical patent/JP2020503841A5/ja
Application granted granted Critical
Publication of JP7213799B2 publication Critical patent/JP7213799B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019519313A 2016-10-10 2017-10-10 非細胞傷害性改変細胞およびその使用 Active JP7213799B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662406005P 2016-10-10 2016-10-10
US62/406,005 2016-10-10
PCT/IL2017/051133 WO2018069927A1 (en) 2016-10-10 2017-10-10 Non-cytotoxic modified cells and use thereof

Publications (3)

Publication Number Publication Date
JP2020503841A JP2020503841A (ja) 2020-02-06
JP2020503841A5 true JP2020503841A5 (enExample) 2020-11-12
JP7213799B2 JP7213799B2 (ja) 2023-01-27

Family

ID=61906189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019519313A Active JP7213799B2 (ja) 2016-10-10 2017-10-10 非細胞傷害性改変細胞およびその使用

Country Status (8)

Country Link
US (2) US12098202B2 (enExample)
EP (1) EP3522936A4 (enExample)
JP (1) JP7213799B2 (enExample)
CN (1) CN110022907A (enExample)
AU (1) AU2017342176A1 (enExample)
CA (1) CA3039774A1 (enExample)
IL (1) IL265962B2 (enExample)
WO (1) WO2018069927A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019221324A1 (en) * 2018-02-15 2020-09-03 The National Institute for Biotechnology in the Negev Ltd. Tumor environment-specific expression of chimeric antigen receptors
WO2019182910A1 (en) * 2018-03-19 2019-09-26 Elwha Llc Compositions and methods for modified b cells expressing reassigned biological agents
EP3825333A4 (en) * 2018-07-06 2022-04-06 Abmax Biopharmaceuticals LOW FUNCTIONALITY ADCC/CDC MONOCLONAL ANTIBODY, METHOD FOR PREPARATION AND USE
KR20210114976A (ko) 2019-01-11 2021-09-24 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 암의 치료 및 예방을 위한 pd-1을 표적으로 하는 dna 단클론성 항체
EP4031669A4 (en) 2019-09-22 2023-01-04 The National Institute for Biotechnology in the Negev, Ltd. TUMOR ENVIRONMENT SPECIFIC EXPRESSION OF EFFECTOR GENES
EP4331631A4 (en) * 2021-04-27 2024-12-11 Beijing Biosis Healing Biological Technology Co., Ltd. CHIMERIC PEPTIDE-MODIFIED SIS MEMBRANE, PRODUCTION METHOD AND APPLICATION THEREOF
CN117736329B (zh) * 2023-12-25 2024-11-12 华润生物医药有限公司 抗pd-1抗体及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153684B1 (en) 1992-10-08 2006-12-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
JP3880795B2 (ja) 1997-10-23 2007-02-14 ジェロン・コーポレーション フィーダー細胞を含まない培養物中で、霊長類由来始原幹細胞を増殖させるための方法
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
US7427665B2 (en) 2000-12-08 2008-09-23 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
ES2384168T3 (es) 2002-04-12 2012-07-02 Medarex, Inc. Procedimientos de tratamiento usando anticuerpos CTLA-4
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US20060275288A1 (en) * 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
JP2008531557A (ja) * 2005-02-23 2008-08-14 メリマック ファーマシューティカルズ インコーポレーティッド 生物活性を調節するための二重特異性結合剤
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
EP2298813A3 (en) 2005-06-06 2012-03-21 Wyeth LLC Anti-TRKB monoclonal antibodies and uses thereof
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
CN101864392B (zh) 2005-12-13 2016-03-23 国立大学法人京都大学 核重新编程因子
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
JP5328018B2 (ja) 2006-06-05 2013-10-30 国立大学法人広島大学 抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞
WO2008019147A2 (en) 2006-08-04 2008-02-14 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
HUE030386T2 (en) * 2007-01-31 2017-05-29 Yeda Res & Dev Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
US10155038B2 (en) * 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
CL2009000090A1 (es) * 2008-01-17 2009-07-24 Irm Llc Anticuerpo que se une al receptor de tirosina quinasa b (trkb); composicion que comprende el anticuerpo; metodo para reducir los niveles de glucosa en la sangre y/o el peso corporal en un individuo.
JP5794917B2 (ja) 2008-09-12 2015-10-14 アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ Ｐｄ−１特異抗体およびその使用
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
US20100261776A1 (en) * 2008-11-07 2010-10-14 The Research Foundation Of State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US20120148586A1 (en) * 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
US9273283B2 (en) * 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US20120263722A1 (en) * 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
GB2491106A (en) 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
AU2015216875B2 (en) * 2014-02-14 2021-02-25 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
EP3593812A3 (en) * 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
CN107567461A (zh) * 2014-12-29 2018-01-09 诺华股份有限公司 制备嵌合抗原受体表达细胞的方法
US20170151281A1 (en) * 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
CN105647946B (zh) * 2016-03-18 2019-09-20 江苏普瑞康生物医药科技有限公司 一种基于FcγRⅢa的嵌合基因及其用途
CA3027546A1 (en) * 2016-06-16 2017-12-21 Alexander Y. RUDENSKY Engineered treg cells

Similar Documents

Publication Publication Date Title
JP7195400B2 (ja) 細胞内抗原に対して指向された単一ドメイン抗体
Suzuki et al. Semaphorins and their receptors in immune cell interactions
US20220040298A1 (en) Use of vista agonists and antagonists to suppress or enhance humoral immunity
Villarino et al. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation
US12516132B2 (en) Anti-PD-L1 nanobody and Fc fusion protein and application thereof
Klein Cytokine-binding proteins: stimulating antagonists
Stoiber et al. Listeria monocytogenes modulates macrophage cytokine responses through STAT serine phosphorylation and the induction of suppressor of cytokine signaling 3
McDyer et al. IL-2 receptor blockade inhibits late, but not early, IFN-γ and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and-independent pathways of IFN-γ production
Muta et al. CD30: from basic research to cancer therapy
CN110945120A (zh) 测量纳米药物中受体-配体相互作用的效力的测定
IL258029B (en) Compounds and methods for joining extracellular complexes of type 1 and 2 as heterologous chimeric proteins
WO2019067677A1 (en) METHODS OF MANUFACTURING RECEPTORS OF ANTI-CD307E ANTI-BACTERIAL CHIMERIC ANTIGENS AND USES THEREFOR
Mizui et al. Immune semaphorins: novel features of neural guidance molecules
FI3443010T3 (fi) Uusia anti-sirp -vasta-aineita ja niiden terapeuttisia sovelluksia
Lin et al. Identification of TAPBPL as a novel negative regulator of T‐cell function
Inoue et al. Characterization of a TNFR2-selective agonistic TNF-α mutant and its derivatives as an optimal regulatory T cell expander
Poudel et al. Induction of IL-12 production by the activation of discoidin domain receptor 2 via NF-κB and JNK pathway
Wu et al. IL-21 signaling promotes IgM+ B cell proliferation and antibody production via JAK/STAT3 and AKT pathways in early vertebrates
Mahesh et al. Expression of GITR ligand abrogates immunosuppressive function of ocular tissue and differentially modulates inflammatory cytokines and chemokines
Klementiev et al. Antiinflammatory properties of a peptide derived from interleukin-4
Senthilkumar et al. CD137L-and RANKL-mediated reverse signals inhibit osteoclastogenesis and T lymphocyte proliferation
Volkov et al. The impact of the intracellular domains of chimeric antigenic receptors on the properties of CAR T-cells
Paul et al. Characterisation of monoclonal antibodies to the TNF and TNF receptor families
Shin et al. Soluble glucocorticoid-induced tumor necrosis factor receptor stimulates osteoclastogenesis by down-regulation of osteoprotegerin in bone marrow stromal cells
Sun et al. Research Note: Development and characterization of monoclonal antibodies specific for chicken interleukin-7 receptor α (CD127)